The notation “13q” refers to the long arm of human chromosome 13, and it shows up across an unusually wide range of medical contexts, from childhood eye cancer to the most common adult leukemia. That breadth is partly explained by the chromosome’s sheer size and partly by the specific genes packed along that arm. Whether you encountered “13q” on a genetic test result, a pathology report, or a prenatal screening, the meaning depends heavily on what happened to that stretch of DNA and in which cells it happened.
What 13q Actually Means
Every human chromosome has a short arm, labeled “p” (from the French petit), and a long arm, labeled “q.” When a lab report says “13q,” it is pointing to the long arm of chromosome 13. Numbers after the “q” narrow the location further: 13q14, for example, pinpoints a specific band visible under a microscope, while 13q14.3 zooms in even more. Chromosome 13 is one of the larger human chromosomes, yet it carries relatively few genes for its size. A sequencing project found only about 6.5 genes per million base pairs across the whole chromosome, and a 38-million-base-pair central stretch drops to just 3.1 genes per million base pairs.1PubMed Central. The DNA sequence and analysis of human chromosome 13 That sparse gene landscape means large chunks of 13q can be lost or rearranged, but the medical consequences vary enormously depending on which genes fall within the affected segment.
Congenital 13q Deletions
Some people are born missing a piece of 13q in every cell. These constitutional deletions usually arise as new events during early embryonic development rather than being inherited from a parent. The clinical picture depends on where along the arm the missing segment falls and how big it is. Researchers have grouped patients into rough categories based on deletion location: those with proximal deletions that stay above band q32 tend to have milder features, while deletions extending through q32 or reaching the terminal end of the arm are associated with more severe problems.
A study of two patients with different deletion regions illustrated this pattern clearly. One patient had an interstitial deletion that did not reach q32 and showed mild intellectual disability with minor physical differences. The other had a terminal deletion reaching q33–q34 and presented with moderate to severe intellectual disability along with major structural abnormalities.2PubMed Central. Phenotypical characterization of 13q deletion syndrome: Report of two cases In a larger group of 14 patients with various 13q deletions, features ranged from profound to mild intellectual disability. Eight had brain anomalies including neural tube defects, six had eye abnormalities, nine had facial differences, and ten had hand or foot anomalies.3Journal of Medical Genetics. 13q Deletion and central nervous system anomalies: further insights from karyotype–phenotype analyses of 14 patients
Research on patients with deletions in the q32 region specifically has pointed to a critical zone whose loss leads to the most severe combination of malformations, particularly involving the fingers and brain. Patients whose deletions overlap this zone share a recognizable pattern, while those whose deletions miss parts of it tend to have fewer and less severe problems.4PubMed Central. The 13q- syndrome: the molecular definition of a critical deletion region in band 13q32 Terminal deletions extending to the very end of the chromosome have been linked to anal atresia, complex heart defects, and gastroesophageal reflux alongside facial differences and developmental delays.5PubMed Central. Chromosome 13q deletion syndrome involving 13q31‑qter: A case report
Deletions Centered on 13q14 and the Retinoblastoma Gene
One of the most clinically significant genes on 13q is RB1, located at band 13q14. This gene acts as a brake on cell division, helping keep growth in check. When both copies of RB1 are knocked out, cells can proliferate unchecked, which is exactly what happens in retinoblastoma, the childhood eye tumor that gave the gene its name.6PubMed Central. Epidemiology and Rb1 gene of retinoblastoma Children born with a constitutional deletion spanning 13q14 are at risk for retinoblastoma, but the deletion often takes out neighboring genes too, producing a broader set of features.
A detailed genotype–phenotype study sorted patients with interstitial 13q deletions encompassing RB1 into three size categories. Those with the smallest deletions, confined within 13q14, could show large head size, tall stature, obesity, and motor or speech delays. Medium deletions spanning 13q12.3 to q21.2 were associated with characteristic facial features, short stature, small head size, and mild to moderate developmental delay. The largest deletions, reaching from 13q12 to q31.2, led to more pronounced craniofacial differences, low muscle tone, feeding difficulties, constipation, and in some cases deafness, seizures, or brain and heart anomalies.7PubMed Central. Genotype–phenotype correlations in patients with retinoblastoma and interstitial 13q deletions The researchers also noted that hemizygous loss of specific neighboring genes appeared to contribute to particular symptoms: one gene was implicated in developmental delay, another in small head size, and a third in feeding difficulties and deafness.
One wrinkle that complicates genetic counseling for retinoblastoma is mosaicism, where only some of a person’s cells carry the RB1 mutation or deletion. A study of retinoblastoma families found that mosaicism is more common than widely assumed, particularly when the mutation arose for the first time rather than being inherited. Testing germ-line DNA separately from blood-cell DNA can reveal mosaic patterns that a standard blood test would miss, and this matters for estimating the chance of passing the mutation to future children.8American Journal of Human Genetics. Mosaicism in Retinoblastoma: Implications for Genetics and Genetic Counseling
Other Key Genes Along 13q
RB1 is the most famous gene on 13q, but it is far from the only medically relevant one. BRCA2, located at 13q13.1, plays a central role in DNA repair. When a cell’s DNA double strand breaks, BRCA2 helps load another protein onto the exposed single-stranded DNA so the break can be fixed accurately using a healthy copy of the sequence as a template.9PubMed Central. Unraveling the mechanism of BRCA2 in homologous recombination Inherited mutations in BRCA2 substantially raise the risk of breast, ovarian, prostate, and pancreatic cancers. Because BRCA2 sits on 13q, large deletions of this arm in tumor cells can knock out this repair pathway, which has direct treatment implications discussed later in this article.
Further along the arm, at 13q14.3, sits ATP7B, the gene responsible for Wilson disease. ATP7B encodes a copper-transporting protein. When both copies carry damaging mutations, copper accumulates in the liver and brain, producing liver disease and neurological symptoms.10PubMed Central. The genetics of Wilson disease The disease follows an autosomal recessive pattern, meaning a person needs two faulty copies to become ill. Carriers with one working copy typically have no symptoms. The connection to 13q matters mainly in that very large constitutional deletions of 13q could, in theory, unmask a recessive ATP7B mutation on the remaining chromosome, though this scenario is extremely rare in practice.
13q Deletions in Chronic Lymphocytic Leukemia
The single most common genetic abnormality in chronic lymphocytic leukemia (CLL) is deletion of part of 13q. This acquired change appears in the leukemia cells themselves, not in every cell of the body, and it involves a small region at 13q14.3 that harbors a cluster of microRNA genes called miR-15a and miR-16-1. These microRNAs normally act as tumor suppressors by dialing down proteins that help cells resist programmed death, most importantly BCL2. When the deletion removes these microRNAs, BCL2 levels rise and the leukemia cells become harder to kill.11PubMed Central. Role of miR-15/16 in CLL The same microRNA cluster also targets other growth-promoting proteins, and its loss has been implicated in cancers beyond CLL, including melanoma, colorectal cancer, and bladder cancer.
The physical mapping of this deletion was a landmark in cancer genetics. Researchers narrowed the critical region to under 300 kilobases of DNA at 13q14 by studying patterns of allelic loss across CLL tumor samples.12PubMed. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia Later work connected the dots to the microRNA cluster, which turned out to be the actual target of the deletion rather than a traditional protein-coding tumor suppressor.
Epigenetic changes at this same locus add another layer. Even in CLL cells that retain 13q14.3, the region can be silenced or activated through chemical modifications to the DNA and its packaging proteins. Two long non-coding RNA genes at 13q14.3, DLEU1 and DLEU2, were found to be epigenetically upregulated in CLL cells, and this correlated with downregulation of neighboring candidate tumor suppressor genes.13PubMed Central. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB So 13q14.3 can be disrupted by outright deletion in some patients and by regulatory rewiring in others, both converging on similar downstream effects.
Why the Size of the Deletion Matters in CLL
Not all 13q deletions in CLL carry the same prognosis. When 13q deletion is the only chromosomal abnormality detected, it generally signals a relatively favorable outlook. In one comprehensive study, about 60% of patients with isolated 13q deletion were alive at five years, compared with 27% for patients whose leukemia cells had a normal result on the same panel of tests.14PubMed Central. A Comprehensive Evaluation of the Prognostic Significance of 13q Deletions in Patients with B-Chronic Lymphocytic Leukemia But within the isolated 13q deletion group, the proportion of leukemia cells carrying the deletion mattered. Patients whose deletion appeared in a smaller fraction of cells (below about two-thirds) had a roughly 79% chance of not needing treatment at five years, while those whose deletion was present in a larger fraction had only a 38% untreated rate at five years.
The physical extent of the deletion also influences outcomes. Smaller deletions confined to the microRNA region behave differently from larger ones that extend to include the RB1 gene. Research found that CLL patients whose 13q deletions spared RB1 and appeared in fewer than 70% of cells had particularly long intervals before needing treatment. In contrast, patients whose deletions reached into RB1 territory, or who had the deletion in 70% or more of cells regardless of deletion size, experienced shorter times to treatment.15Genes, Chromosomes and Cancer. 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia The percentage of affected cells remained a strong predictor even after accounting for other well-known prognostic markers.
13q in Multiple Myeloma and Solid Tumors
CLL is not the only blood cancer where 13q deletions show up. In multiple myeloma, loss of material from chromosome 13 is very common, but the pattern differs. Rather than a small, focused deletion at 13q14, myeloma cells tend to lose most or all of the 13q arm, sometimes the entire chromosome.16PubMed. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy The prognostic significance has been debated over the years, but a recent study of myeloma patients who had undergone stem-cell transplants found that isolated 13q deletion or monosomy 13 was independently linked to shorter progression-free survival (about 37 months vs. 65 months) and shorter overall survival (about 105 months vs. 131 months) compared with patients who had neither this deletion nor other high-risk chromosomal abnormalities. When 13q loss coincided with other high-risk changes, outcomes were worst of all.17British Journal of Haematology. Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation
Solid tumors also show loss of 13q material. In hepatocellular carcinoma (liver cancer), allelic loss along 13q was found in nearly half of tumors studied and was more frequent in larger tumors and those at more advanced stages. Two sub-regions stood out: 13q12.3–14.1, associated with advanced tumor stage, and 13q32, associated with larger tumor size.18AACR Journals (Clinical Cancer Research). Clinicopathological Significance of Loss of Heterozygosity on Chromosome 13q in Hepatocellular Carcinoma These findings suggest that 13q harbors tumor-suppressor genes relevant to liver cancer that may not yet be fully characterized.
How 13q Abnormalities Are Detected
Different clinical settings call for different detection methods. In blood cancers like CLL, a technique called fluorescence in situ hybridization (FISH) has long been the standard. FISH uses fluorescent probes that stick to specific chromosomal regions, making it easy to spot a missing segment. However, array-based comparative genomic hybridization (aCGH) can pick up abnormalities that FISH misses. In one head-to-head comparison of 55 CLL cases, FISH detected genetic abnormalities in 60% of cases, while aCGH found them in 82%. The array identified abnormalities missed by FISH in about 16% of cases.19International Journal of Laboratory Hematology. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia That said, FISH has the advantage of measuring the percentage of cells carrying the deletion, which as discussed above carries its own prognostic weight in CLL.
For congenital 13q deletions, detection sometimes begins prenatally. Non-invasive prenatal testing (NIPT), which analyzes fragments of fetal DNA circulating in the mother’s blood, can flag large chromosomal gains or losses. Researchers have confirmed that NIPT can detect sub-chromosomal deletions on chromosome 13, with array testing of fetal cells subsequently confirming the findings.20PubMed Central. Genetic effects of a 13q31.1 microdeletion detected by noninvasive prenatal testing (NIPT) Complex deletion patterns involving chromosomes 13 and 21 have also been successfully identified through NIPT.21PubMed Central. Detection of complex deletions in chromosomes 13 and 21 in a fetus by noninvasive prenatal testing Still, NIPT is not infallible. A case report documented a terminal deletion of 13q in a fetus whose NIPT result had come back normal, highlighting the continued importance of invasive testing (amniocentesis or chorionic villus sampling) when ultrasound findings raise suspicion even after a reassuring NIPT screen.22PubMed Central. Terminal deletion of chromosome 13 in a fetus with normal NIPT: The added value of invasive prenatal diagnosis in the NIPT era
Ring Chromosomes Involving 13q
A less common structural rearrangement is a ring chromosome 13, in which the two ends of the chromosome break and then fuse into a circular structure, losing the material beyond the break points. Ring chromosomes are inherently unstable: during cell division they can be lost entirely, duplicate, or form double-ring structures. This instability creates mosaicism, meaning different cells in the same person carry different chromosome complements. In one case study, the ring chromosome 13 was present in about 90% of blood cells, while roughly 9% of cells had lost chromosome 13 entirely and about 1% contained a double-ring structure.23North American Journal of Medicine and Science. Interstitial Duplication and Distal Deletion in a Ring Chromosome 13 with Pulmonary Atresia and Ventricular Septal Defect: A Case Report and Review of Literature The same patient’s ring chromosome also carried an internal duplication alongside a terminal deletion, showing that ring formation can scramble the arm’s content in complex ways.
Ring instability also complicates the clinical picture through a mechanism called inv-dup-del, where part of the chromosome is duplicated in an inverted orientation while the terminal segment is deleted. This has been documented in ring chromosome 13 patients and can explain why some individuals with ring 13 have features more severe than a simple terminal deletion would predict.24PubMed Central. Mechanisms of ring chromosome formation, ring instability and clinical consequences
Treatment Implications of 13q Status
Knowing the 13q status of a tumor is not just academic bookkeeping. In CLL, the deletion of miR-15a/16-1 leads to overexpression of BCL2, which is precisely the protein targeted by the drug venetoclax. Early laboratory work has explored whether biallelic deletion (loss of both copies) of 13q might blunt venetoclax’s effectiveness, since the drug relies on BCL2 dependence, and complete loss of the miR-15/16 brake could shift the survival machinery toward other proteins. Indeed, CLL samples with biallelic 13q deletion showed diminished responses to venetoclax under certain stimulating conditions compared with samples retaining at least one copy.25Blood. Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents This line of research is still evolving, but it underscores how deletion mapping feeds directly into treatment strategy.
In prostate cancer, the co-deletion of genes on 13q has implications for PARP inhibitor therapy. PARP inhibitors work by exploiting a tumor’s inability to repair DNA breaks, and they are effective against tumors with BRCA2 loss. However, when RNASEH2B (also on 13q) is lost alongside RB1, the sensitivity to PARP inhibitors can be overridden, blunting the drug’s effect. Encouragingly, additional loss of BRCA2 in these co-deleted cells restored sensitivity to PARP inhibition.26Science Advances. RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer Understanding which 13q genes are lost in a given tumor thus helps predict whether certain targeted drugs will work. The FDA has granted breakthrough designation to the PARP inhibitor olaparib for metastatic castration-resistant prostate cancers carrying BRCA1/2 or ATM mutations, making the molecular characterization of 13q deletions a practical step in treatment planning.27PubMed Central. Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations
Evolutionary Perspective on Chromosome 13
The arrangement of genes on chromosome 13 is not fixed across species. Comparative studies using chromosome painting in primates have revealed that the block of DNA corresponding to human chromosome 13 exists as two separate chromosomes in certain New World monkeys like the cotton-top tamarin and the silvery marmoset, while it remains a single syntenic unit in the howler monkey. A survey of the OMIM database identified 109 disease loci with well-characterized phenotypes on chromosome 13, along with 519 cancer breakpoints catalogued in the Mitelman database.28PubMed Central. Evolution of the Human Chromosome 13 Synteny: Evolutionary Rearrangements, Plasticity, Human Disease Genes and Cancer Breakpoints The concentration of cancer breakpoints suggests that certain regions of 13q are structurally fragile, prone to the very rearrangements that drive tumor development. Whether these fragile sites in humans correspond to the evolutionary breakpoints seen in other primates is an active area of investigation, and it hints that the architecture of 13q has been under rearrangement pressure for millions of years.